ALX Oncology (NASDAQ:ALXO) Posts Earnings Results, Misses Estimates By $0.04 EPS

ALX Oncology (NASDAQ:ALXO) posted its quarterly earnings data on Friday. The company reported ($0.42) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.04), Zacks reports.

Here are the key takeaways from ALX Oncology’s conference call:

• Evorpacept (EVO)
• The Phase 2 ASPEN‑09‑Breast trial has been expanded from 80 to up to 120 patients and the primary endpoint was refocused to response rate in CD47‑high patients, with top‑line data for the 80‑patient cohort expected in mid‑2027 and a companion diagnostic in development.
• ALX2004 (EGFR‑targeted ADC) is in dose escalation (now dosing 4 mg/kg after clearing 1 and 2 mg/kg cohorts); company expects full dose‑escalation safety data in H2 2026 and highlights preclinical signals of potent activity with limited ILD/skin toxicity in NHP studies.
• ALX completed an equity financing (gross $150M; net ~$140.4M) and says cash on hand now supports operations through the first half of 2028, strengthening the balance sheet to fund near‑term catalysts across both programs.
• Q4 GAAP net loss narrowed to $22.8M from $29.2M a year earlier and management says spending will be concentrated on EVO and ALX2004 while legacy trials wind down, reducing some near‑term spend but concentrating program risk on two assets.

ALX Oncology Stock Performance

Shares of ALXO stock opened at $2.11 on Friday. The company has a market capitalization of $114.40 million, a P/E ratio of -1.04 and a beta of 0.51. ALX Oncology has a fifty-two week low of $0.40 and a fifty-two week high of $2.66. The company has a debt-to-equity ratio of 0.13, a quick ratio of 2.40 and a current ratio of 2.40. The stock has a 50 day moving average price of $1.70 and a two-hundred day moving average price of $1.50.

Insider Activity

In other news, Director Corey S. Goodman bought 3,184,713 shares of the firm’s stock in a transaction that occurred on Monday, February 2nd. The shares were bought at an average cost of $1.57 per share, with a total value of $4,999,999.41. Following the completion of the purchase, the director directly owned 8,453,038 shares in the company, valued at $13,271,269.66. This represents a 60.45% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at this link. Corporate insiders own 21.00% of the company’s stock.

Institutional Investors Weigh In On ALX Oncology

A number of large investors have recently added to or reduced their stakes in ALXO. Invesco Ltd. purchased a new position in shares of ALX Oncology in the first quarter valued at about $46,000. Bridgeway Capital Management LLC purchased a new position in ALX Oncology during the 3rd quarter valued at about $66,000. AQR Capital Management LLC raised its position in ALX Oncology by 183.6% during the 1st quarter. AQR Capital Management LLC now owns 119,050 shares of the company’s stock valued at $74,000 after purchasing an additional 77,065 shares during the last quarter. Jane Street Group LLC purchased a new stake in ALX Oncology in the 2nd quarter worth approximately $84,000. Finally, State Street Corp grew its position in shares of ALX Oncology by 11.0% in the 4th quarter. State Street Corp now owns 124,228 shares of the company’s stock worth $140,000 after buying an additional 12,300 shares during the last quarter. Institutional investors own 97.97% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the company. Wall Street Zen upgraded ALX Oncology from a “sell” rating to a “hold” rating in a research report on Monday, December 22nd. Jefferies Financial Group began coverage on ALX Oncology in a report on Thursday, November 13th. They set a “buy” rating and a $4.00 price objective on the stock. Piper Sandler boosted their target price on ALX Oncology from $3.00 to $4.00 and gave the stock an “overweight” rating in a research report on Thursday, February 5th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of ALX Oncology in a research report on Wednesday, January 21st. Four research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $2.50.

ALX Oncology Company Profile

ALX Oncology, Inc is a clinical-stage biopharmaceutical company headquartered in Redwood City, California, focused on developing next-generation immuno-oncology therapies. The company’s mission is to harness and amplify both innate and adaptive immune responses to improve outcomes for patients with a range of solid tumors and hematologic malignancies.

The lead candidate in ALX Oncology’s pipeline is evorpacept (ALX148), a high-affinity CD47-blocking Fc-silenced fusion protein designed to enhance macrophage-mediated phagocytosis of cancer cells when combined with standard therapeutic antibodies or immune checkpoint inhibitors.

Featured Stories

• Five stocks we like better than ALX Oncology
• 3 Signs You May Want to Switch Financial Advisors
• Unlocked: Elon Musk’s Next Big IPO
• Buffett, Gates and Bezos Quietly Dumping Stocks—Here’s Why
• 1,500 Banks Just Handed the Fed Your Bank Account
• The Man Who Predicted the iPhone Says Buy These 3 Companies